ArticlePharmaceutics2023
An Efficient Peptidomics Screening for Exogenous Substrates and Inhibitory Peptides of the Dipeptidase ACE from Milk Hydrolysate.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
The dipeptidase angiotensin-I-converting enzyme (ACE) pre-incubation, liquid chromatography- mass spectrometry (LC-MS), and stable-isotope labeling were integrated for an efficient screening of ACE's exogenous substrates from milk hydrolysate. Using this approach, 31 substrates were readily identified from 478 identified peptides and their activities were confirmed using synthetic peptides. Their reactivity is highly correlated with the decreased isotope ratio observed in LC-MS. Among these substrates, the most frequently observed residue at the P1' position was Leu/Ser. It also revealed that ACE would not cleave the peptide when P1' is Pro, P2' is Asp/Glu, or P1 position is Ile. Interestingly, the sequential two-stage hydrolysis was also found. Moreover, their protective effects against ACE-mediated hydrolysis of angiotensin I (Ang-I) were also examined. The result indicated that AYFYPELFR and HLPLPLLQSW can significantly retard the hydrolysis of Ang-I and act as substrate-type inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.